Literature DB >> 11163473

Developing a nontypeable Haemophilus influenzae (NTHi) vaccine.

J T Poolman1, L Bakaletz, A Cripps, P A Denoel, A Forsgren, J Kyd, Y Lobet.   

Abstract

There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, ellipsis) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11163473     DOI： 10.1016/s0264-410x(00)00288-7

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  39 in total

1.  Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotype d, strain KW20.

Authors:  Alistair Harrison; David W Dyer; Allison Gillaspy; William C Ray; Rachna Mungur; Matthew B Carson; Huachun Zhong; Jenny Gipson; Mandy Gipson; Linda S Johnson; Lisa Lewis; Lauren O Bakaletz; Robert S Munson
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

2.  Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.

Authors:  Johan Berglund; Peter Vink; Fernanda Tavares Da Silva; Pascal Lestrate; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

3.  Recognition of conserved antigens by Th17 cells provides broad protection against pulmonary Haemophilus influenzae infection.

Authors:  Wenchao Li; Xinyun Zhang; Ying Yang; Qingqin Yin; Yan Wang; Yong Li; Chuan Wang; Sandy M Wong; Ying Wang; Howard Goldfine; Brian J Akerley; Hao Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

4.  The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.

Authors:  Kerry-Ann F O'Grady; Anne B Chang; Allan Cripps; Edward K Mulholland; Heidi Smith-Vaughan; Nicholas Wood; Margaret Danchin; Ruth Thornton; Andrew Wilson; Paul J Torzillo; Peter M Morris; Peter Richmond; Sheree Rablin; Daniel Arnold; Ann Connor; Vikas Goyal; Tanya Stoney; Kirsten Perrett; Keith Grimwood
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

5.  Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Vaccine       Date:  2010-12-01       Impact factor: 3.641

6.  Mucosal immunization of mice with recombinant OMP P2 induces antibodies that bind to surface epitopes of multiple strains of nontypeable Haemophilus influenzae.

Authors:  K L Ostberg; M W Russell; T F Murphy
Journal:  Mucosal Immunol       Date:  2008-10-29       Impact factor: 7.313

7.  Safety and immunological outcomes following human inoculation with nontypeable Haemophilus influenzae.

Authors:  Patricia L Winokur; Kathryn Chaloner; Gary V Doern; Jennifer Ferreira; Michael A Apicella
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

8.  Differential uptake and processing of a Haemophilus influenzae P5-derived immunogen by chinchilla dendritic cells.

Authors:  Laura A Novotny; Santiago Partida-Sánchez; Robert S Munson; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2007-12-26       Impact factor: 3.441

9.  Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx.

Authors:  Jennelle M Kyd; Allan W Cripps; Laura A Novotny; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Identification of potential therapeutic targets for Burkholderia cenocepacia by comparative transcriptomics.

Authors:  Deborah R Yoder-Himes; Konstantinos T Konstantinidis; James M Tiedje
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.